There have been several studies on the clinical outcomes of Radium-223 treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) who may have an increased risk of hematologic comorbidities. To the best of our knowledge, this is the first study to explore the potential bone marrow adverse effects (AEs) of Radium-223 administered with specific drugs used for hematologic conditions, such as polycythemia vera (PV). We report the case of a patient with mCRPC who was administered a combined treatment of Radium-223 and hydroxyurea for PV, aiming to support clinicians in predicting eventual AEs.

Radium-223 treatment in mcrpc patient with polycythemia vera / de Angelis, C.; Frantellizzi, V.; Pontico, M.; de Feo, M. S.; Lazri, J.; de Vincentis, G.. - In: MOLECULAR IMAGING AND RADIONUCLIDE THERAPY. - ISSN 2146-1414. - 30:3(2021), pp. 193-196. [10.4274/mirt.galenos.2020.58661]

Radium-223 treatment in mcrpc patient with polycythemia vera

de Angelis C.
Primo
;
Frantellizzi V.
Secondo
;
Pontico M.
;
de Feo M. S.;Lazri J.
Penultimo
;
de Vincentis G.
Ultimo
2021

Abstract

There have been several studies on the clinical outcomes of Radium-223 treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) who may have an increased risk of hematologic comorbidities. To the best of our knowledge, this is the first study to explore the potential bone marrow adverse effects (AEs) of Radium-223 administered with specific drugs used for hematologic conditions, such as polycythemia vera (PV). We report the case of a patient with mCRPC who was administered a combined treatment of Radium-223 and hydroxyurea for PV, aiming to support clinicians in predicting eventual AEs.
File allegati a questo prodotto
File Dimensione Formato  
De Angelis_Radium-223_2021.pdf

accesso aperto

Note: https://mirt.tsnmjournals.org/archives/archive-detail/article-preview/radium-223-treatment-in-mcrpc-patient-with-polycyt/49281
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 628.71 kB
Formato Adobe PDF
628.71 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1590335
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact